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ABSTRACT 
Haloperidol is a classic antipsychotic drug known for its propensity to cause extrapyramidal 
symptoms due to blockade of dopamine D2 receptors in the striatum. Interest in medicinal 
uses of cannabis is growing. Cannabis sativa has been suggested as a possible adjunctive in 
treatment of Parkinson's disease. The present study aimed to investigate the effect of repeated 
administration of an extract of Cannabis sativa on catalepsy and brain oxidative stress in-
duced by haloperidol administration in mice. Cannabis extract was given by subcutaneous 
route at 5, 10 or 20 mg/kg (expressed as ∆9-tetrahydrocannabinol) once daily for 18 days and 
the effect on haloperidol (1 mg/kg, i.p.)-induced catalepsy was examined at selected time in-
tervals using the bar test. Mice were euthanized 18 days after starting cannabis injection when 
biochemical assays were carried out. Malondialdehyde (MDA), reduced glutathione (GSH) 
and nitric oxide (the concentrations of nitrite/nitrate) were determined in brain and liver. In 
saline-treated mice, no catalepsy was observed at doses of cannabis up to 20 mg/kg. Mice 
treated with haloperidol at the dose of 1 mg/kg, exhibited significant cataleptic response. 
Mice treated with cannabis and haloperidol showed significant decrease in catalepsy duration, 
compared with the haloperidol only treated group. This decrease in catalepsy duration was 
evident on days 1-12 after starting cannabis injection. Later the effect of cannabis was not ap-
parent. The administration of only cannabis (10 or 20 mg/kg) decreased brain MDA by 
17.5 and 21.8 %, respectively. The level of nitric oxide decreased by 18 % after cannabis at 
20 mg/kg. Glucose in brain decreased by 20.1 % after 20 mg/kg of cannabis extract. The ad-
ministration of only haloperidol increased MDA (22.2 %), decreased GSH (25.7 %) and in-
creased brain nitric oxide by 44.1 %. The administration of cannabis (10 or 20 mg/kg) to 
haloperidol-treated mice resulted in a significant decrease in brain MDA and nitric oxide as 
well as a significant increase in GSH and glucose compared with the haloperidol-control 
group. Cannabis had no significant effects on liver MDA, GSH, nitric oxide in saline or 
haloperidol-treated mice. It is concluded that cannabis improves catalepsy induced by 
haloperidol though the effect is not maintained on repeated cannabis administration. Cannabis 
alters the oxidative status of the brain in favor of reducing lipid peroxidation, but reduces 
brain glucose, which would impair brain energetics. 
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INTRODUCTION 
Cannabis preparations are the most 
widely used illicit drugs worldwide. They 
are derived from the female plant of Can-
nabis sativa Linn (Family Cannabidaceae). 
Marijuana is prepared from the dried flow-
ering tops and leaves; hashish consists of 
dried cannabis resin and compressed flow-
ers. The primary psychoactive constituent is 
∆9-tetrahydrocannabinol (THC) (Gaoni and 
Mechoulam, 1964; Ashton, 2001). Other 
plant cannabinoids include ∆8-THC, canna-
binol, cannabidiol and cannabichromene. 
These and other cannabinoids have addi-
tive, synergistic or antagonistic effects with 
THC and may modify its actions when 
herbal cannabis is smoked (Russo and 
McPartland, 2003; DeLong et al., 2010; 
Long et al., 2010). Cannabinoids exert their 
effects by acting on specific receptors. Two 
subtypes of cannabinoid receptors have 
been identified so far; CB1 and CB2 recep-
tors. The former is expressed strongly in the 
basal ganglia, cerebellum, olfactory areas, 
cortex, and hippocampus, which accounts 
for the well-known effects of cannabis on 
cognition, memory reward, motor coordina-
tion and short-term-memory processing. 
CB1 is also expressed at high concentra-
tions in the dorsal primary afferent spinal-
cord regions, which are important in pain 
pathways. In contrast, CB2 receptor is ex-
pressed mainly in peripheral tissues and is 
predominantly associated with the immune 
system (Pertwee and Ross, 2002; Pertwee, 
2005, 2008). 
Interest in medicinal uses of cannabis is 
growing. THC extracts (i.e. Sativex) or 
THC derivatives such as nabilone and 
dronabinol are used in the clinic for the 
treatment of several pathological conditions 
like chemotherapy-induced nausea and 
vomiting, multiple sclerosis and glaucoma 
(Gerra et al., 2010). Cannabinoids might 
also prove useful as anticancer agents (Li-
gresti et al., 2006; Vara et al., 2011) and in 
neurodegenerative diseases (Iuvone et al., 
2009; Basavarajappa et al., 2009). In multi-
ple sclerosis patients, symptomatic im-
provement, particularly for muscle stiffness 
and spasms, neuropathic pain and sleep and 
bladder disturbance has been reported when 
using oromucosal spray of whole plant ex-
tract containing equal proportions of ∆9-
tetrahydrocannabinol and cannabidiol (Sa-
tivex) (Lakhan and Rowland, 2009; Sastre-
Garriga et al., 2011; Zajicek and Apostu, 
2011). Some form of benefit has been also 
described in a significant proportion of 
Parkinson's disease patients taking cannabis 
(Venderová et al., 2004). Central canna-
binoid receptors are densely located in the 
output nuclei of the basal ganglia (globus 
pallidus, substantia nigra pars reticulata), 
suggesting their involvement in the regula-
tion of motor activity (Müller-Vahl et al., 
1999). Cannabinoids may prove useful in 
Parkinson's disease by inhibiting the exci-
totoxic neurotransmitter glutamate and 
counteracting oxidative damage to dopa-
minergic neurons. The inhibitory effect of 
cannabinoids on reactive oxygen species, 
glutamate and tumour necrosis factor also 
suggested likely neuroprotective properties 
for cannabis (Croxford, 2003). Cannabis 
extracts or their psychoactive constituent 
∆9-THC, have been reported, however, to 
cause catalepsy in rodents. The latter is a 
state of postural immobility (akinesia) with 
muscular rigidity which can model human 
Parkinson’s disease. Haloperidol is a classic 
antipsychotic used in the treatment of schiz-
phrenia that is well known for its propensity 
to cause extrapyramidal symptoms, effects 
that are mediated by a blockade of striatal 
D2 receptors (Jibson and Tandon, 1998). 
Catalepsy caused in rodents by haloperidol 
is a widely accepted model of the Parkin-
son’s-like side effects caused by typical an-
tipsychotics in humans (Hoffman and Do-
novan, 1995). Catalepsy occurs when more 
than 80 % of D2 receptors are occupied by 
the drug (Wadenberg et al., 2001).  
In light of the above data, the present 
study was designed to (1) investigate the 
ability of a cannabis extract with known ∆9-
THC content to alter catalepsy produced by 
the D2 receptor antagonist haloperidol in 
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mice; (2) examine the effects of cannabis 
administration on antioxidant reserve and 
oxidative stress markers in brain under the-
se experimental conditions. A total extract 
from Cannabis sativa was used based on 
the fact that the effect of the whole plant 
which is abused by humans differs from 
that of THC in view of its content of other 
cannabinoids, terpenoids and flavonoids 
(Russo and McPartland, 2003). 
 
MATERIALS AND METHODS 
Animals 
Swiss male albino mice 20-22 g of body 
weight (age: 5-6 weeks) were used. Mice 
were obtained from animal house colony of 
the National Research Centre (Cairo, 
Egypt). Mice were housed under standard-
ized conditions with free access to standard 
laboratory food and water. Animal proce-
dures were performed in accordance with 
the Ethics Committee of the National Re-
search Centre and followed the recommen-
dations of the National Institutes of Health 
Guide for Care and Use of Laboratory An-
imals (Publication No. 85-23, revised 
1985). Equal groups of 6 mice each were 
used in all experiments.  
 
Plant material and extraction 
Cannabis sativa L. plant was supplied 
by the Ministry of Justice- Egypt. Extract of 
Cannabis sativa L. was obtained by chloro-
form treatment, and contained 10 % of ∆9-
THC as determined by (GC mass) gas-
chromatography. 
 
Dry extract of Cannabis sativa 
Cannabis sativa extract was prepared 
from the dried flowering tops and leaves of 
the plant. The method of extraction fol-
lowed that described by Turner and Mahl-
berg (1984) with modification. In brief, 
10 g of dried cannabis was ground with a 
mortar and pestle. Decarboxylation of the 
plant material was achieved by placing the 
sample in a glass test tube (30 mL) and 
covering it with aluminum foil. The test 
tubes were placed in boiling water bath 
(100 ºC) for 2 h. Ten milliliters of analyti-
cal grade chloroform was added and al-
lowed to react for 1 h. The dried cannabis 
was extracted three times and fractions 
were combined, filtered over filter paper 
and collected in a 100 mL volumetric flask. 
The filtrate was evaporated under a gentle 
stream of nitrogen (on ice and protected 
from light and stored at 4 ºC and protected 
from light in an aluminum-covered contain-
er, which provided the dry extract as resi-
due. 
 
Preparation of diluted extract for injection 
The residue (dry extract) is suspended 
in 2 mL of 96 % ethanol and the total vol-
ume in the volumetric flask increased to 
100 mL by adding distilled water. The ex-
tract was injected subcutaneously at doses 
of 5, 10 and 20 mg/kg (expressed as ∆9-
THC). The injection volume was 0.1, 0.2 
and 0.3 ml/mouse, respectively. Tetrahy-
drocannabinol (THC) content was quanti-
fied using “GC mass spec”. The dry extract 
contained 10 % of the ∆9-THC. Canna-
binoids are enzymatically biosynthesised in 
the plant as their corresponding carboxylic 
acid forms (Taura et al., 2007). Neutral 
cannabinoids are formed via decarboxyla-
tion (loss of CO2) of the acidic canna-
binoids during exposure to light, heat (e.g. 
smoking), or as a result of prolonged stor-
age (Thakur et al., 2005) (Scheme 1).  
The decarboxylation is carried out by 
heat in water bath at 100 oC for 2 h. The 
1H-NMR proves that there is no signal cor-
responding to the carboxylic acid (COOH) 
around 12-13 ppm. 
 
 
 
 
Scheme 1: The decarboxylation of the acidic 
cannabinoids: tetrahydrocannabinolic acid 
(THCA) to delta 9-tetrahydrocannabinol (∆9THC). 
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Study design 
The following groups were studied: 
Saline normal mice 
5 mg/kg cannabis-treated mice 
10 mg/kg cannabis-treated mice  
20 mg/kg cannabis-treated mice  
5 mg/kg cannabis-treated mice + haloperi-
dol 1 mg/kg 
10 mg/kg cannabis-treated mice + haloperi-
dol 1 mg/kg 
20 mg/kg cannabis-treated mice + haloperi-
dol 1 mg/kg 
 
Catalepsy 
Cannabis extract was given by subcuta-
neous route at 5, 10 or 20 mg/kg (expressed 
as ∆9-THC) (together with haloperidol 1 
mg/kg, i.p.) once daily for 18 days. Mice 
thereafter were tested for the presence of 
catalepsy at selected time intervals. Cata-
lepsy, defined as a reduced ability to initiate 
movement and a failure to correct abnormal 
posture, was measured by means of the bar 
test. To test for catalepsy, mice were posi-
tioned so that their hindquarters were on the 
bench and their forelimbs rested on a 1 cm 
diameter horizontal bar, 4 cm above the 
bench. This procedure was conducted 30 
min after drug administration. The length of 
time the mice maintained this position was 
recorded by stopwatch to a maximum of 
180 s (mean of three consecutive trials; in-
ter-trial interval: 1 min). Mice were judged 
to be cataleptic if they maintained this posi-
tion for 30 s or more. 
 
Biochemical analysis 
Mice were euthanized 24 days after 
starting cannabis injection by decapitation 
under ether anaesthesia, brains and livers 
were excised, washed with ice-cold saline 
solution (0.9 % NaCl), weighed and stored 
at -80 ºC for the biochemical analyses. The 
liver was homogenized with 0.1 M phos-
phate buffer saline at pH 7.4, to give a final 
concentration of 10 % w/v for the biochem-
ical assays.  
 
Determination of lipid peroxidation 
Lipid peroxidation was assayed by 
measuring the level of malondialdehyde 
(MDA) in the brain and liver tissues. 
Malondialdehyde was determined by meas-
uring thiobarbituric reactive species using 
the method of Ruiz-Larrea et al. (1994), in 
which the thiobarbituric acid reactive sub-
stances react with thiobarbituric acid to 
produce a red colored complex having peak 
absorbance at 532 nm. 
 
Determination of reduced glutathione  
Reduced glutathione (GSH) was deter-
mined by Ellman's method (1959). The pro-
cedure is based on the reduction of 
Ellman´s reagent by –SH groups of GSH to 
form 2-nitro-s-mercaptobenzoic acid, the 
nitromercaptobenzoic acid anion has an in-
tense yellow color which can be determined 
spectrophotometrically. 
 
Determination of nitric oxide  
Nitric oxide measured as nitrite was de-
termined by using Griess reagent, according 
to the method of Moshage et al. (1995) 
where nitrite, stable end product of nitric 
oxide radical, is mostly used as indicator 
for the production of nitric oxide 
 
Determination of brain glucose 
Brain tissue glucose content was deter-
mined according to the method of Trinder 
(1969). Glucose in the presence of glucose 
oxidase is converted to peroxide and glu-
conic acid. The produced hydrogen perox-
ide reacts with phenol and 4-amino-
antipyrine in the presence of peroxidase to 
yield a colored quinonemine, which is 
measured spectrophotometrically. 
 
Analysis of data 
Drug effects on haloperidol-induced be-
haviors and biochemical changes were ex-
pressed as the mean ± SEM. Data were ana-
lyzed with a one-way ANOVA followed by 
post hoc comparisons using Duncan’s mul-
tiple range test.  
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RESULTS 
Catalepsy 
Results are shown in Figure 1. Cannabis 
given to saline treated mice failed to induce 
catalepsy. Haloperidol administered i.p. at 
the dose of 1 mg/kg produced a significant 
cataleptic response. Starting on the first day 
of cannabis administration till the 9th day, 
the duration of haloperidol-induced catalep-
sy was significantly reduced by cannabis in 
a dose-dependent manner. On the 12th day 
of drug injection, the duration of catalepsy 
was decreased by cannabis at 5 and 10 
mg/kg. On the 15th day of drug injection, 
the duration of catalepsy was decreased by 
cannabis at 5 mg/kg.  
Figure 1: Effect of daily administration of Can-
nabis sativa extract on the duration of catalepsy 
(sec) induced by haloperidol administration over 
18 days in mice. Data showed the duration of 
catalepsy on day 1, 3, 9, 15 and 18 of treat-
ment. Columns 1-4 represent haloperidol con-
trol, haloperidol + cannabis 5, 10 or 20 mg/kg, 
respectively. Asterisks indicate significant 
change from the haloperidol control group. 
Cannabis given to saline treated mice failed to 
induce catalepsy (not shown). 
 
BIOCHEMICAL RESULTS 
Effect of cannabis on brain oxidative 
stress 
The administration of cannabis at 10 or 
20 mg/kg to saline treated mice significant-
ly decreased brain MDA by 17.5 and 
21.8 %, respectively (21.2 ± 1.0 and 20.1 ± 
0.8 vs 25.7 ± 1.3 nmol/g, p<0.05) (Fig-
ure 2). GSH increased by 18.0 % after can-
nabis given at 20 mg/kg (3.9 ± 0.16 vs 3.5 ± 
0.15 µmol/g, p<0.05) (Figure 3), while ni-
tric oxide decreased by 18.3 % (21.0 ± 1.0 
vs 25.6 ± 1.5 µmol/g, p<0.05) after canna-
bis (20 mg/kg) injection compared with the 
saline control group (Figure 4).  
Figure 2: Effect of Cannabis sativa extract on 
brain malondialdehyde (nmol/ g. tissue) in sa-
line- or haloperidol-treated mice. Asterisks indi-
cate significant change from the saline treated 
group. The plus (+) sign indicates significant 
change from the haloperidol control group.  
Figure 3: Effect of Cannabis sativa extract on 
brain reduced glutathione (µmol/ g. tissue) in 
saline- or haloperidol-treated mice. Asterisks 
indicate significant change from the saline 
treated group. The plus (+) sign indicates signif-
icant change from the haloperidol control group.  
 
The administration of haloperidol 
(1 mg/kg, i.p.) significantly increased MDA 
by 22.2 % compared with the saline control 
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group (31.4 ± 1.7 vs 25.7 ± 1.3 nmol/g, 
p<0.05) (Figure 2). Meanwhile, GSH de-
creased by 25.7 % (2.6 ± 0.18 vs 3.5 ± 0.15 
µmol/g, p<0.05) (Figure 3) and nitric oxide 
increased by 44.1 % (36.9 ± 1.8 vs 25.6 ± 
1.5 µmol/g, p<0.05) by haloperidol treat-
ment (Figure 4). In haloperidol-treated 
mice, however, MDA decreased by 17.8 
and 28 % after cannabis administration at 
doses of 10 or 20 mg/kg, respectively (25.8 
± 1.4 and 22.6 ± 1.3 vs 31.4 ± 1.7 nmol/g) 
(Figure 2). In addition, the administration 
of cannabis at 10 or 20 mg/kg resulted in 
19.2 and 30.8 % increase in GSH, respec-
tively (3.1 ± 0.10 and 3 .4 ± 0.12 vs 2.6 ± 
0.18 µmol/g, p<0.05) (Figure 3). Mean-
while, the level of nitric oxide decreased by 
17.3 % (30.5 ± 1.8 vs 36.9 ± 1.8, p<0.05) 
after the administration of 20 mg/kg of can-
nabis (Figure 4). 
Figure 4: Effect of Cannabis sativa extract on 
brain nitric oxide (µmol/g tissue) in saline- or 
haloperidol-treated mice. Asterisks indicate sig-
nificant change from the saline treated group. 
The plus (+) sign indicates significant change 
from the haloperidol control group.  
 
Effect of cannabis on brain glucose 
In saline-treated mice, cannabis admin-
istration at 10 or 20 mg/kg resulted in sig-
nificant decrease in brain glucose by 12.4 
and 20.1 %, respectively compared with the 
saline control group (39.7 ± 1.4 and 36.2 ± 
1.5 vs 45.3 ± 1.2 µg/g, p<0.05). Haloperidol 
treatment had no significant effect on brain 
glucose. In haloperidol-treated mice, how-
ever, cannabis at 10 or 20 mg/kg, signifi-
cantly decreased glucose by 17 and 21 %, 
respectively as compared with the haloperi-
dol only treated group (40.5 ± 2.1 and 38.6 
± 1.8 vs 48.8 ± 1.3 µg/g, p<0.05)(Figure 5).  
 
Figure 5: Effect of Cannabis sativa extract on 
brain glucose (µg/g tissue) in saline- or 
haloperidol-treated mice. Asterisks indicate sig-
nificant change from the saline treated group. 
The plus (+) sign indicates significant change 
from the haloperidol control group.  
 
 
Effect of cannabis on liver oxidative stress 
Liver MDA, GSH or nitric oxide was 
not significantly altered by the administra-
tion of only cannabis, haloperidol or canna-
bis-haloperidol (Table 1). 
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Table 1: Effect of Cannabis sativa extract on liver malondialdehyde (MDA), reduced glutathione 
(GSH), nitric oxide (NO) and glucose in saline- and haloperidol-treated mice 
 
 MDA (nmol/g tissue) GSH (µmol/g tissue) NO (µmol/g tissue) 
Saline 63.3 ± 3.1 10.6 ± 1.1 106.8 ± 11.1 
Cannabis 5 mg/kg 66.2 ± 2.7 9.3 ± 1.7 118.6 ± 10.7 
Cannabis 10 mg/kg 64.6 ± 3.1 9.5 ± 1.1 110.4 ± 8.1 
Cannabis 20 mg/kg 61.5 ± 0.7 9.52 ± 0.7 110.3 ± 9.7 
Haloperidol 1 mg/kg 67.5 ± 1.9 8.9 ± 0.9 110.5 ± 6.9 
+ Cannabis 5 mg/kg 65.7 ±1.4 8.9 ± 0.4 112.4 ± 7.4 
+ Cannabis 10 mg/kg 63.6 ± 3.7 9.2 ± 0.7 110.6 ± 8.7 
+ Cannabis 20 mg/kg 62.9 ± 1.5 9.4 ± 0.5 110.1 ± 5.5 
Values represent the mean ± S.E. of six mice for each group 
 
 
DISCUSSION 
This study investigated the effect of 
cannabis extract with known ∆9-THC con-
tent on haloperidol-induced catalepsy and 
on oxidative stress in brain of mice. The 
present findings indicate that the single and 
repeated daily administration of the extract 
at doses corresponding to 5, 10 and 20 mg 
∆9-THC/kg by itself failed to induce cata-
lepsy in mice. Haloperidol, an antipsychotic 
used in humans, is well known to cause ex-
trapyramidal symptoms, due to blockade of 
dopamine D2 receptors in the striatum. 
Haloperidol administered subcutaneously at 
1 mg/kg induced significant catalepsy. 
Cannabis initially decreased catalepsy in-
duced by haloperidol. On repeated admin-
istration, the effect of cannabis was not ap-
parent. These observations contradict other 
studies that reported a cataleptogenic re-
sponse in rodents following the single ad-
ministration of cannabis extracts or their 
psychoactive constituent ∆9-THC. In rats, 
catalepsy has been reported following in-
travenous (12.5 mg/kg), intraperitoneal or 
subcutaneous (100 mg/kg) administrations 
of cannabis extract (Pertwee, 1972) as well 
as marijuana (200 mg) smoke inhalation 
(Varvel et al., 2005). Rats or mice adminis-
tered ∆9-THC intravenously (Kataoka et al., 
1987; Kinoshita et al., 1994) or intraperito-
neally (5-20 mg/kg) (Pertwee and Green-
tree, 1998) also exhibited cataleptogenic 
response. Catalepsy caused by ∆9-THC 
Catalepsy caused by ∆9-THC or cannabis 
extracts was attenuated by 6-hydroxy-
dopamine, lesions of locus coeruleus, non-
competitive N-methyl-D-aspartate (NMDA) 
antagonist (Kataoka et al., 1987), fluraze-
pam or chlordiazepoxide pretreatment 
(Pertwee and Greentree, 1998), atropine (3 
mg/kg, sc) (Ferri et al., 1981), serotonergic 
drugs or antiglutamatergic drugs (Sano et 
al., 2008). Other researchers have reported 
that haloperidol, but not clozapine, induced 
intense rat catalepsy when co-administered 
with ∆9-tetrahydrocannabinol (Marchese et 
al., 2003). 
The failure of cannabis extract in the 
present study to cause catalepsy or to en-
hance that due to haloperidol is likely to be 
due to the different methods of extraction 
employed in different studies, leading to the 
extraction of ∆9-THC together with signifi-
cant proportion of other cannabinoids such 
as cannabinol, cannabidiol, cannabichro-
mene, cannabipinol, cannabidivarin and 
others, being present or other yet unidenti-
fied constituents that modulated or antago-
nized the cataleptogenic effect of ∆9-THC. 
Other possibility is that large doses of ∆9-
THC are required to elicit a cataleptogenic 
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response. Other cannabinoids have additive, 
synergistic or antagonistic effects with ∆9-
THC and may modify its actions when 
herbal cannabis is smoked (Russo and 
McPartland, 2003; Hayakawa et al., 2008). 
In support of this notion studies showing 
that the action of cannabis is quite different 
from that of pure ∆9-THC. For example, 
while both a standardized cannabis extract 
and ∆9-THC inhibited spasticity in a mouse 
model of multiple sclerosis to comparable 
level, the former caused a more rapid onset 
of muscle relaxation. In the chronic relaps-
ing experimental autoimmune encephalo-
myelitis mouse model of multiple sclerosis, 
chronic administration of ∆9-THC-rich ex-
tract (though not cannabidiol-rich extract or 
combined treatment with ∆9-THC- and can-
nabidiol-rich extracts) resulted in a signifi-
cant reduction of neurological deficits 
(Buccellato et al., 2011). ∆9-THC and can-
nabidiol, a non-psychoactive component of 
cannabis had clearly distinct effects on neu-
ral activation with the former having anxio-
genic effects in contrast to cannabidiol-
induced anxiolytic effects (Fusar-Poli et al., 
2009, 2010; Bhattacharyya et al., 2009). 
Cannabis extract, but not ∆9-THC, revealed 
a significant reduction of right-hand tapping 
frequencies that was also found in schizo-
phrenia (Roser et al., 2009). In vitro, stand-
ard cannabis extract as well as ∆9-THC-free 
extract but not ∆9-THC exerted anticonvul-
sant activity (Wilkinson et al., 2003). Other 
researchers observed that either ∆9-THC or 
to lesser extent cannabidiol induced a cata-
tonic response in mice. When both com-
pounds were injected simultaneously (2.5, 5 
or 10 mg/kg of each), however, a clear in-
hibition of the catatonic effect of ∆9-THC 
was seen (Karniol and Carlini, 1973). Can-
nabidiol blocked certain effects of ∆9-THC: 
catatonia in mice, corneal areflexia in rab-
bits, increased defecation and decreased 
ambulation in rats in the open field after 
chronic administration and aggressiveness 
in rats after REM-sleep deprivation. In con-
trast, cannabidiol potentiated ∆9-THC anal-
gesia in mice and the impairment of rope 
climbing in rats (Russo and Guy, 2006). ∆9-
THC is subject to first-pass metabolism by 
the liver. The metabolism of ∆9-THC is by 
hydroxylation and oxidation catalyzed by 
the cytochrome P450 enzyme (CYP) sys-
tem. The major two metabolites of ∆9-THC 
are 11-hydroxy-∆9-THC and 11-nor-9-
carboxy-∆9-THC. The former is a com-
pound that is more psychoactive than THC 
itself (Hazekamp and Grotenhermen, 2010). 
CYP2C9 and CYP3A4 are the major en-
zymes involved in the 11-hydroxylation and 
the 8-(or the 7-) hydroxylation, respective-
ly, of the cannabinoids by human hepatic 
microsomes (Yamamoto et al., 2003; 
Watanabe et al., 2007). The main enzymes 
responsible for the formation of 11-OH-
THC are CYP2C and the ratio of oxidized 
metabolites formed is dependent on popula-
tion of CYPs present in hepatic microsomes 
of the experimental animals (Yamamoto et 
al., 2003). The in vivo liver metabolism of 
Δ9-THC and cannabidiol differed in the 
mouse and rat (Harvey et al., 1977). Dis-
crepancies between Δ9-THC effects shown 
here and data from the literature may be 
also due to the species used, i.e. mice which 
differ from rats in their specificity and ca-
pacity to metabolize THC.  
In the rat, akinetic catalepsy induced by 
haloperidol can model human Parkinson’s 
disease which occurs when more than 80 % 
of D2 receptors are occupied by the drug 
(Wadenberg et al., 2001; Natesan et al., 
2006). Catalepsy due to haloperidol can be 
blocked by D2 dopamine receptor agonists 
(Moratalla et al., 1996), adenosine receptor 
antagonists (Trevitt et al., 2009), by alpha2 
receptor antagonists (Imaki et al., 2009) or 
by 5-HT1A agonists (Prinssen et al., 2002). 
The current observations that cannabis did 
not enhance motor impairment due to D2 
receptor blockade by haloperidol, also sug-
gest that cannabis preparations are unlikely 
to worsen Parkinsonian symptoms. There is 
evidence that cannabis might in fact in-
crease dopamine release in human striatum 
(Voruganti et al., 2001; Bossong et al., 
2009) or in rodent brain (Cheer et al., 
EXCLI Journal 2012;11:45-58 – ISSN 1611-2156 
Received: December 15, 2011, accepted: February 21, 2012, published: February 24, 2012 
 
53 
2004). Δ9-THC, the endocannabinoid anan-
damide as well as the synthetic cannabinoid 
receptor agonist WIN 55,212-2 inhibited 
the enzyme monoamine oxidase (MAO) 
which catalyzes inactivation of monoam-
ines, including neurotransmitters, such as 
dopamine, norepinephrine, and serotonin 
(Fišar, 2010).This in addition to an antioxi-
dant effect (Hampson et al., 1998, 2000) 
might underlie their symptomatic effect in 
patients with Parkinson's disease (Vendero-
vá et al., 2004) as well as their neuroprotec-
tive effects reported in vitro as well as in 
experimental animals (van der Stelt, 2001; 
Gilbert et al., 2007). Moreover, in the 1-
methyl-1,2,3,6-tetrahydropyridine (MPTP)-
marmoset model for Parkinson’s disease, 
∆9-THC improved activity and hand-eye 
coordination (van Vliet et al., 2008). The 
effect of cannabis on catalepsy in the pre-
sent study can be ascribed to a dopamine 
releasing effect by the extract. It was noted 
that the lower dose of the extract was more 
effective in decreasing the duration of cata-
lepsy. This occurs despite no effect on oxi-
dative stress. It is likely that at the higher 
doses of cannabis, other neurotransmitter 
systems are affected eg., effect on 5-
HT(1A) and or alpha(2)-adrenoceptors 
(Zanelati et al., 2010; Cascio et al., 2010; 
Fišar, 2010; Kleijn et al., 2011).  
In the striatum, acetylcholine (ACh) is 
another neurotransmitter that plays an im-
portant role in the genesis of Parkinsonian 
symptoms and anticholinergic drugs are 
used in early stages and to decrease Parkin-
son’s tremor (Schrag et al., 1999; Tarsy, 
2006). Inconsistent results have been re-
ported however, as regards the effect of 
cannabinoids on acetylcholine release in the 
striatum. For example, ∆9-THC 5 mg/kg 
and cannabiodiol 20 mg/kg produced a sig-
nificant decrease in ACh turnover in the 
striatum (Revuelta et al., 1978), while ∆9-
THC (30 mg/kg) caused a significant eleva-
tion of ACh in cortex, hippocampus, stria-
tum, mid brain and medulla-pons (Tripathi 
et al., 1987). Other researchers, however, 
reported inhibition by ∆8-THC and ∆9-THC 
of the synthesis of 3H-ACh in cortex, hypo-
thalamus, and striatum rat brain (Friedman 
et al., 1976). Synthetic cannabinoids were 
also found to inhibit ACh release in the rat 
hippocampus (Gessa et al., 1997).  
The effect of cannabis sativa on brain 
oxidative stress is important in view of the 
evidence linking increased oxidative stress 
to a number of neurodegenerative diseases 
including Parkinson’s disease. The present 
studies suggest that cannabis extract alters 
the oxidative balance in the brain. Unex-
pectedly, the administration of cannabis for 
one month decreased malondialdehyde, a 
marker of lipid peroxidation (Gutteridge, 
1995). Reduced glutathione, an important 
antioxidant defense system is increased, 
especially with the highest dose of cannabis 
examined. Nitric oxide in brain also de-
creased by cannabis administration. One 
notable finding, however, was the de-
creased brain glucose by cannabis admin-
istration, thereby impairing cerebral energy 
metabolism. The antioxidant effects of can-
nabis in brain must thus be weighed against 
a decrease in brain energetics (glucose de-
crease possibly underlying their cognitive 
impairing effects observed in humans as 
well as in rodents). Meanwhile and in con-
trast to the effect of repeated cannabis ex-
tract on oxidative stress in brain, the extract 
did no affect lipid peroxidation or reduced 
glutathione levels in the liver tissue in sa-
line- or haloperidol-treated mice. 
The present findings also indicated in-
creased oxidative stress in the brain by 
haloperidol administration, which is in ac-
cordance with other researchers (Polydoro 
et al., 2004). There was increased nitric ox-
ide, decreased glutathione and increased 
lipid peroxidation. These changes were 
ameliorated by the administration of canna-
bis extract. These results can be explained 
by the fact that cannabis extract is not only 
∆9-THC, but it contained other canna-
binoids, some of them were found to exert 
neuroprotective effects. The decrease in 
brain lipid peroxidation by the cannabis ex-
tract can be ascribed to the other canna-
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binoids or flavenoids eg. flavocannabiside 
or flavosativaside it contains. In rat cortical 
neuron cultures exposed to toxic levels of 
glutamate, ∆9-THC and cannabidiol re-
duced NMDA, AMPA and Kainate recep-
tor-mediated neurotoxicities by cannabinoid 
receptor-independent mechanism of action 
(Hampson et al., 2000). Moreover, systemic 
administration of a cannabinoid modulator 
that enhances anandamide availability ex-
erted antiparkinsonian effects in 6-
hydroxydopamine-lesioned rats through 
stimulation of 5-HT1B receptor function 
(Fernandez-Espejo et al., 2004).  
In summary, short term cannabis admin-
istration was effective in reducing the cata-
leptic response to haloperidol. On repeated 
cannabis administration, this effect however 
was markedly reduced. The biochemical 
alterations (increased nitric oxide decreased 
glutathione and increased lipid peroxida-
tion) induced in brain by haloperidol was 
ameliorated by the administration of canna-
bis extract.  
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